nodes	percent_of_prediction	percent_of_DWPC	metapath
Atomoxetine—CYP2D6—Fingolimod—multiple sclerosis	0.0721	0.214	CbGbCtD
Atomoxetine—CYP3A4—Fingolimod—multiple sclerosis	0.0459	0.136	CbGbCtD
Atomoxetine—HTR1B—trigeminal nucleus—multiple sclerosis	0.0419	0.176	CbGeAlD
Atomoxetine—HTR1D—trigeminal nucleus—multiple sclerosis	0.0406	0.171	CbGeAlD
Atomoxetine—CYP2C19—Prednisone—multiple sclerosis	0.037	0.11	CbGbCtD
Atomoxetine—CYP3A4—Methylprednisolone—multiple sclerosis	0.0295	0.0878	CbGbCtD
Atomoxetine—HTR1D—meninx—multiple sclerosis	0.027	0.113	CbGeAlD
Atomoxetine—CYP2C19—Dexamethasone—multiple sclerosis	0.0231	0.0687	CbGbCtD
Atomoxetine—CYP3A4—Triamcinolone—multiple sclerosis	0.0224	0.0666	CbGbCtD
Atomoxetine—CYP3A4—Mitoxantrone—multiple sclerosis	0.0216	0.0641	CbGbCtD
Atomoxetine—HTR2A—trigeminal nucleus—multiple sclerosis	0.0202	0.0848	CbGeAlD
Atomoxetine—CYP3A4—Betamethasone—multiple sclerosis	0.0192	0.0571	CbGbCtD
Atomoxetine—CYP3A4—Prednisolone—multiple sclerosis	0.019	0.0563	CbGbCtD
Atomoxetine—CYP3A4—Prednisone—multiple sclerosis	0.0179	0.0532	CbGbCtD
Atomoxetine—CYP2D6—Dexamethasone—multiple sclerosis	0.0176	0.0522	CbGbCtD
Atomoxetine—CYP3A4—Dexamethasone—multiple sclerosis	0.0112	0.0332	CbGbCtD
Atomoxetine—HTR1B—trigeminal nerve—multiple sclerosis	0.011	0.0463	CbGeAlD
Atomoxetine—HTR1D—trigeminal nerve—multiple sclerosis	0.0107	0.0448	CbGeAlD
Atomoxetine—NPY1R—nerve—multiple sclerosis	0.00948	0.0399	CbGeAlD
Atomoxetine—HTR2A—trigeminal nerve—multiple sclerosis	0.0053	0.0223	CbGeAlD
Atomoxetine—SLC6A3—nerve—multiple sclerosis	0.00399	0.0168	CbGeAlD
Atomoxetine—HTR2A—pons—multiple sclerosis	0.00373	0.0157	CbGeAlD
Atomoxetine—SLC6A2—nerve—multiple sclerosis	0.00322	0.0135	CbGeAlD
Atomoxetine—HTR2A—pineal body—multiple sclerosis	0.00266	0.0112	CbGeAlD
Atomoxetine—HTR2A—peripheral nervous system—multiple sclerosis	0.00248	0.0104	CbGeAlD
Atomoxetine—NPY1R—nervous system—multiple sclerosis	0.00213	0.00897	CbGeAlD
Atomoxetine—NPY1R—central nervous system—multiple sclerosis	0.00205	0.00863	CbGeAlD
Atomoxetine—HTR2A—nerve—multiple sclerosis	0.00193	0.00813	CbGeAlD
Atomoxetine—Pseudoephedrine—IL2—multiple sclerosis	0.00184	0.373	CrCbGaD
Atomoxetine—HTR1B—brainstem—multiple sclerosis	0.00173	0.00726	CbGeAlD
Atomoxetine—SLC6A3—brainstem—multiple sclerosis	0.00171	0.0072	CbGeAlD
Atomoxetine—HTR1D—brainstem—multiple sclerosis	0.00167	0.00703	CbGeAlD
Atomoxetine—HTR2C—brainstem—multiple sclerosis	0.00166	0.00696	CbGeAlD
Atomoxetine—NPY1R—brain—multiple sclerosis	0.00163	0.00685	CbGeAlD
Atomoxetine—SLC6A4—brainstem—multiple sclerosis	0.00157	0.0066	CbGeAlD
Atomoxetine—HTR6—nervous system—multiple sclerosis	0.0015	0.00631	CbGeAlD
Atomoxetine—HTR6—central nervous system—multiple sclerosis	0.00145	0.00608	CbGeAlD
Atomoxetine—SLC6A2—brainstem—multiple sclerosis	0.00138	0.00581	CbGeAlD
Atomoxetine—HTR2C—medulla oblongata—multiple sclerosis	0.00115	0.00485	CbGeAlD
Atomoxetine—HTR6—brain—multiple sclerosis	0.00115	0.00482	CbGeAlD
Atomoxetine—HTR1B—midbrain—multiple sclerosis	0.0011	0.00463	CbGeAlD
Atomoxetine—SLC6A3—midbrain—multiple sclerosis	0.00109	0.00459	CbGeAlD
Atomoxetine—HTR1B—spinal cord—multiple sclerosis	0.00107	0.00451	CbGeAlD
Atomoxetine—HTR1D—midbrain—multiple sclerosis	0.00107	0.00448	CbGeAlD
Atomoxetine—SLC6A3—spinal cord—multiple sclerosis	0.00107	0.00448	CbGeAlD
Atomoxetine—HTR2C—midbrain—multiple sclerosis	0.00106	0.00444	CbGeAlD
Atomoxetine—HTR2C—spinal cord—multiple sclerosis	0.00103	0.00433	CbGeAlD
Atomoxetine—SLC6A4—midbrain—multiple sclerosis	0.001	0.00421	CbGeAlD
Atomoxetine—SLC6A4—spinal cord—multiple sclerosis	0.000976	0.0041	CbGeAlD
Atomoxetine—SLC6A2—medulla oblongata—multiple sclerosis	0.000964	0.00405	CbGeAlD
Atomoxetine—HTR1B—nervous system—multiple sclerosis	0.000905	0.0038	CbGeAlD
Atomoxetine—SLC6A3—nervous system—multiple sclerosis	0.000897	0.00377	CbGeAlD
Atomoxetine—HTR1D—nervous system—multiple sclerosis	0.000876	0.00368	CbGeAlD
Atomoxetine—HTR1B—central nervous system—multiple sclerosis	0.000871	0.00366	CbGeAlD
Atomoxetine—HTR2C—nervous system—multiple sclerosis	0.000868	0.00365	CbGeAlD
Atomoxetine—SLC6A3—central nervous system—multiple sclerosis	0.000864	0.00363	CbGeAlD
Atomoxetine—SLC6A3—cerebellum—multiple sclerosis	0.000845	0.00355	CbGeAlD
Atomoxetine—HTR1D—central nervous system—multiple sclerosis	0.000843	0.00355	CbGeAlD
Atomoxetine—Ephedrine—BCHE—multiple sclerosis	0.000843	0.171	CrCbGaD
Atomoxetine—HTR2C—central nervous system—multiple sclerosis	0.000835	0.00351	CbGeAlD
Atomoxetine—HTR2A—brainstem—multiple sclerosis	0.000831	0.00349	CbGeAlD
Atomoxetine—SLC6A4—nervous system—multiple sclerosis	0.000822	0.00346	CbGeAlD
Atomoxetine—HTR2A—retina—multiple sclerosis	0.000801	0.00337	CbGeAlD
Atomoxetine—SLC6A4—central nervous system—multiple sclerosis	0.000792	0.00333	CbGeAlD
Atomoxetine—CYP2D6—brainstem—multiple sclerosis	0.000757	0.00318	CbGeAlD
Atomoxetine—SLC6A2—nervous system—multiple sclerosis	0.000724	0.00304	CbGeAlD
Atomoxetine—SLC6A2—central nervous system—multiple sclerosis	0.000697	0.00293	CbGeAlD
Atomoxetine—HTR1B—brain—multiple sclerosis	0.000692	0.00291	CbGeAlD
Atomoxetine—SLC6A3—brain—multiple sclerosis	0.000686	0.00288	CbGeAlD
Atomoxetine—HTR1D—brain—multiple sclerosis	0.00067	0.00281	CbGeAlD
Atomoxetine—HTR2C—brain—multiple sclerosis	0.000663	0.00279	CbGeAlD
Atomoxetine—SLC6A4—brain—multiple sclerosis	0.000629	0.00264	CbGeAlD
Atomoxetine—Pseudoephedrine—TNF—multiple sclerosis	0.00062	0.126	CrCbGaD
Atomoxetine—HTR2A—medulla oblongata—multiple sclerosis	0.000579	0.00243	CbGeAlD
Atomoxetine—SLC6A2—brain—multiple sclerosis	0.000553	0.00233	CbGeAlD
Atomoxetine—HTR2A—midbrain—multiple sclerosis	0.000529	0.00223	CbGeAlD
Atomoxetine—HTR2A—spinal cord—multiple sclerosis	0.000516	0.00217	CbGeAlD
Atomoxetine—HTR2A—nervous system—multiple sclerosis	0.000435	0.00183	CbGeAlD
Atomoxetine—HTR2A—central nervous system—multiple sclerosis	0.000419	0.00176	CbGeAlD
Atomoxetine—HTR2A—cerebellum—multiple sclerosis	0.00041	0.00172	CbGeAlD
Atomoxetine—CYP3A4—nervous system—multiple sclerosis	0.000403	0.00169	CbGeAlD
Atomoxetine—CYP2D6—nervous system—multiple sclerosis	0.000396	0.00167	CbGeAlD
Atomoxetine—CYP3A4—central nervous system—multiple sclerosis	0.000388	0.00163	CbGeAlD
Atomoxetine—CYP2D6—central nervous system—multiple sclerosis	0.000382	0.0016	CbGeAlD
Atomoxetine—CYP2D6—cerebellum—multiple sclerosis	0.000373	0.00157	CbGeAlD
Atomoxetine—Fenoprofen—ALB—multiple sclerosis	0.00036	0.073	CrCbGaD
Atomoxetine—HTR2A—brain—multiple sclerosis	0.000333	0.0014	CbGeAlD
Atomoxetine—Phenprocoumon—ALB—multiple sclerosis	0.000311	0.063	CrCbGaD
Atomoxetine—Feeling abnormal—Mitoxantrone—multiple sclerosis	0.000305	0.00107	CcSEcCtD
Atomoxetine—Dysuria—Methotrexate—multiple sclerosis	0.000304	0.00107	CcSEcCtD
Atomoxetine—Dizziness—Azathioprine—multiple sclerosis	0.000303	0.00106	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	0.000303	0.00106	CcSEcCtD
Atomoxetine—CYP2D6—brain—multiple sclerosis	0.000303	0.00127	CbGeAlD
Atomoxetine—Fluoxetine—ALB—multiple sclerosis	0.000302	0.0613	CrCbGaD
Atomoxetine—Upper respiratory tract infection—Methotrexate—multiple sclerosis	0.000302	0.00106	CcSEcCtD
Atomoxetine—Loss of consciousness—Triamcinolone—multiple sclerosis	0.000301	0.00106	CcSEcCtD
Atomoxetine—Loss of consciousness—Methylprednisolone—multiple sclerosis	0.0003	0.00105	CcSEcCtD
Atomoxetine—Shock—Prednisolone—multiple sclerosis	0.000299	0.00105	CcSEcCtD
Atomoxetine—Erectile dysfunction—Methotrexate—multiple sclerosis	0.000299	0.00105	CcSEcCtD
Atomoxetine—Cough—Triamcinolone—multiple sclerosis	0.000299	0.00105	CcSEcCtD
Atomoxetine—Convulsion—Triamcinolone—multiple sclerosis	0.000297	0.00104	CcSEcCtD
Atomoxetine—Tachycardia—Prednisolone—multiple sclerosis	0.000297	0.00104	CcSEcCtD
Atomoxetine—Convulsion—Methylprednisolone—multiple sclerosis	0.000296	0.00104	CcSEcCtD
Atomoxetine—Urticaria—Mitoxantrone—multiple sclerosis	0.000294	0.00103	CcSEcCtD
Atomoxetine—Hyperhidrosis—Prednisolone—multiple sclerosis	0.000294	0.00103	CcSEcCtD
Atomoxetine—Abdominal pain—Mitoxantrone—multiple sclerosis	0.000293	0.00103	CcSEcCtD
Atomoxetine—Body temperature increased—Mitoxantrone—multiple sclerosis	0.000293	0.00103	CcSEcCtD
Atomoxetine—Myalgia—Triamcinolone—multiple sclerosis	0.000292	0.00102	CcSEcCtD
Atomoxetine—Vomiting—Azathioprine—multiple sclerosis	0.000291	0.00102	CcSEcCtD
Atomoxetine—Arthralgia—Methylprednisolone—multiple sclerosis	0.000291	0.00102	CcSEcCtD
Atomoxetine—Myalgia—Methylprednisolone—multiple sclerosis	0.000291	0.00102	CcSEcCtD
Atomoxetine—Anxiety—Methylprednisolone—multiple sclerosis	0.00029	0.00102	CcSEcCtD
Atomoxetine—Infestation—Methotrexate—multiple sclerosis	0.00029	0.00102	CcSEcCtD
Atomoxetine—Infestation NOS—Methotrexate—multiple sclerosis	0.00029	0.00102	CcSEcCtD
Atomoxetine—Rash—Azathioprine—multiple sclerosis	0.000289	0.00101	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000289	0.00101	CcSEcCtD
Atomoxetine—Dermatitis—Azathioprine—multiple sclerosis	0.000289	0.00101	CcSEcCtD
Atomoxetine—Depression—Methotrexate—multiple sclerosis	0.000289	0.00101	CcSEcCtD
Atomoxetine—Flushing—Prednisone—multiple sclerosis	0.000289	0.00101	CcSEcCtD
Atomoxetine—Headache—Azathioprine—multiple sclerosis	0.000287	0.00101	CcSEcCtD
Atomoxetine—Dry mouth—Triamcinolone—multiple sclerosis	0.000285	0.001	CcSEcCtD
Atomoxetine—Angiopathy—Prednisone—multiple sclerosis	0.000282	0.00099	CcSEcCtD
Atomoxetine—Conjunctivitis—Methotrexate—multiple sclerosis	0.000281	0.000987	CcSEcCtD
Atomoxetine—Vertigo—Dexamethasone—multiple sclerosis	0.000279	0.00098	CcSEcCtD
Atomoxetine—Vertigo—Betamethasone—multiple sclerosis	0.000279	0.00098	CcSEcCtD
Atomoxetine—Syncope—Betamethasone—multiple sclerosis	0.000279	0.000978	CcSEcCtD
Atomoxetine—Syncope—Dexamethasone—multiple sclerosis	0.000279	0.000978	CcSEcCtD
Atomoxetine—Infection—Triamcinolone—multiple sclerosis	0.000278	0.000975	CcSEcCtD
Atomoxetine—Infection—Methylprednisolone—multiple sclerosis	0.000277	0.000972	CcSEcCtD
Atomoxetine—Warfarin—ALB—multiple sclerosis	0.000276	0.0559	CrCbGaD
Atomoxetine—Shock—Triamcinolone—multiple sclerosis	0.000275	0.000965	CcSEcCtD
Atomoxetine—Insomnia—Prednisolone—multiple sclerosis	0.000275	0.000965	CcSEcCtD
Atomoxetine—Shock—Methylprednisolone—multiple sclerosis	0.000274	0.000963	CcSEcCtD
Atomoxetine—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000274	0.00096	CcSEcCtD
Atomoxetine—Loss of consciousness—Dexamethasone—multiple sclerosis	0.000273	0.000959	CcSEcCtD
Atomoxetine—Loss of consciousness—Betamethasone—multiple sclerosis	0.000273	0.000959	CcSEcCtD
Atomoxetine—Paraesthesia—Prednisolone—multiple sclerosis	0.000273	0.000958	CcSEcCtD
Atomoxetine—Tachycardia—Triamcinolone—multiple sclerosis	0.000273	0.000957	CcSEcCtD
Atomoxetine—Mental disorder—Prednisone—multiple sclerosis	0.000272	0.000956	CcSEcCtD
Atomoxetine—Nausea—Azathioprine—multiple sclerosis	0.000272	0.000955	CcSEcCtD
Atomoxetine—Tachycardia—Methylprednisolone—multiple sclerosis	0.000272	0.000955	CcSEcCtD
Atomoxetine—Skin disorder—Methylprednisolone—multiple sclerosis	0.000271	0.000951	CcSEcCtD
Atomoxetine—Malnutrition—Prednisone—multiple sclerosis	0.000271	0.00095	CcSEcCtD
Atomoxetine—Hyperhidrosis—Triamcinolone—multiple sclerosis	0.00027	0.000948	CcSEcCtD
Atomoxetine—Hyperhidrosis—Methylprednisolone—multiple sclerosis	0.00027	0.000946	CcSEcCtD
Atomoxetine—Convulsion—Betamethasone—multiple sclerosis	0.000269	0.000945	CcSEcCtD
Atomoxetine—Convulsion—Dexamethasone—multiple sclerosis	0.000269	0.000945	CcSEcCtD
Atomoxetine—Asthenia—Mitoxantrone—multiple sclerosis	0.000266	0.000933	CcSEcCtD
Atomoxetine—Myalgia—Betamethasone—multiple sclerosis	0.000265	0.000929	CcSEcCtD
Atomoxetine—Myalgia—Dexamethasone—multiple sclerosis	0.000265	0.000929	CcSEcCtD
Atomoxetine—Anxiety—Betamethasone—multiple sclerosis	0.000264	0.000925	CcSEcCtD
Atomoxetine—Anxiety—Dexamethasone—multiple sclerosis	0.000264	0.000925	CcSEcCtD
Atomoxetine—Pain—Prednisolone—multiple sclerosis	0.00026	0.000912	CcSEcCtD
Atomoxetine—Urinary tract disorder—Methotrexate—multiple sclerosis	0.000257	0.000901	CcSEcCtD
Atomoxetine—Vision blurred—Prednisone—multiple sclerosis	0.000255	0.000895	CcSEcCtD
Atomoxetine—Urethral disorder—Methotrexate—multiple sclerosis	0.000255	0.000894	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.000255	0.000894	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.000254	0.000892	CcSEcCtD
Atomoxetine—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000254	0.00089	CcSEcCtD
Atomoxetine—Insomnia—Triamcinolone—multiple sclerosis	0.000253	0.000887	CcSEcCtD
Atomoxetine—Insomnia—Methylprednisolone—multiple sclerosis	0.000252	0.000885	CcSEcCtD
Atomoxetine—Infection—Dexamethasone—multiple sclerosis	0.000252	0.000884	CcSEcCtD
Atomoxetine—Infection—Betamethasone—multiple sclerosis	0.000252	0.000884	CcSEcCtD
Atomoxetine—Paraesthesia—Triamcinolone—multiple sclerosis	0.000251	0.000881	CcSEcCtD
Atomoxetine—Feeling abnormal—Prednisolone—multiple sclerosis	0.000251	0.000879	CcSEcCtD
Atomoxetine—Paraesthesia—Methylprednisolone—multiple sclerosis	0.000251	0.000879	CcSEcCtD
Atomoxetine—Shock—Dexamethasone—multiple sclerosis	0.00025	0.000876	CcSEcCtD
Atomoxetine—Shock—Betamethasone—multiple sclerosis	0.00025	0.000876	CcSEcCtD
Atomoxetine—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000249	0.000873	CcSEcCtD
Atomoxetine—Nervous system disorder—Betamethasone—multiple sclerosis	0.000249	0.000873	CcSEcCtD
Atomoxetine—Agitation—Prednisone—multiple sclerosis	0.000249	0.000873	CcSEcCtD
Atomoxetine—Tachycardia—Betamethasone—multiple sclerosis	0.000248	0.000869	CcSEcCtD
Atomoxetine—Tachycardia—Dexamethasone—multiple sclerosis	0.000248	0.000869	CcSEcCtD
Atomoxetine—Dyspepsia—Triamcinolone—multiple sclerosis	0.000246	0.000864	CcSEcCtD
Atomoxetine—Dyspepsia—Methylprednisolone—multiple sclerosis	0.000246	0.000862	CcSEcCtD
Atomoxetine—Hyperhidrosis—Dexamethasone—multiple sclerosis	0.000245	0.000861	CcSEcCtD
Atomoxetine—Hyperhidrosis—Betamethasone—multiple sclerosis	0.000245	0.000861	CcSEcCtD
Atomoxetine—Vertigo—Prednisone—multiple sclerosis	0.000243	0.000853	CcSEcCtD
Atomoxetine—Syncope—Prednisone—multiple sclerosis	0.000243	0.000852	CcSEcCtD
Atomoxetine—Anorexia—Dexamethasone—multiple sclerosis	0.000242	0.000849	CcSEcCtD
Atomoxetine—Anorexia—Betamethasone—multiple sclerosis	0.000242	0.000849	CcSEcCtD
Atomoxetine—Urticaria—Prednisolone—multiple sclerosis	0.000242	0.000847	CcSEcCtD
Atomoxetine—Cardiac disorder—Methotrexate—multiple sclerosis	0.000241	0.000846	CcSEcCtD
Atomoxetine—Fatigue—Triamcinolone—multiple sclerosis	0.000241	0.000846	CcSEcCtD
Atomoxetine—Fatigue—Methylprednisolone—multiple sclerosis	0.000241	0.000844	CcSEcCtD
Atomoxetine—Pain—Triamcinolone—multiple sclerosis	0.000239	0.000839	CcSEcCtD
Atomoxetine—Loss of consciousness—Prednisone—multiple sclerosis	0.000238	0.000835	CcSEcCtD
Atomoxetine—Angiopathy—Methotrexate—multiple sclerosis	0.000236	0.000827	CcSEcCtD
Atomoxetine—Vomiting—Mitoxantrone—multiple sclerosis	0.000236	0.000827	CcSEcCtD
Atomoxetine—Convulsion—Prednisone—multiple sclerosis	0.000235	0.000823	CcSEcCtD
Atomoxetine—Mediastinal disorder—Methotrexate—multiple sclerosis	0.000234	0.000822	CcSEcCtD
Atomoxetine—Rash—Mitoxantrone—multiple sclerosis	0.000234	0.00082	CcSEcCtD
Atomoxetine—Dermatitis—Mitoxantrone—multiple sclerosis	0.000233	0.000819	CcSEcCtD
Atomoxetine—Chills—Methotrexate—multiple sclerosis	0.000233	0.000818	CcSEcCtD
Atomoxetine—Headache—Mitoxantrone—multiple sclerosis	0.000232	0.000815	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.000231	0.000811	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.000231	0.000811	CcSEcCtD
Atomoxetine—Myalgia—Prednisone—multiple sclerosis	0.00023	0.000809	CcSEcCtD
Atomoxetine—Arthralgia—Prednisone—multiple sclerosis	0.00023	0.000809	CcSEcCtD
Atomoxetine—Feeling abnormal—Triamcinolone—multiple sclerosis	0.00023	0.000808	CcSEcCtD
Atomoxetine—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.00023	0.000807	CcSEcCtD
Atomoxetine—Anxiety—Prednisone—multiple sclerosis	0.00023	0.000806	CcSEcCtD
Atomoxetine—Insomnia—Betamethasone—multiple sclerosis	0.000229	0.000805	CcSEcCtD
Atomoxetine—Insomnia—Dexamethasone—multiple sclerosis	0.000229	0.000805	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000229	0.000803	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000228	0.0008	CcSEcCtD
Atomoxetine—Paraesthesia—Betamethasone—multiple sclerosis	0.000228	0.000799	CcSEcCtD
Atomoxetine—Paraesthesia—Dexamethasone—multiple sclerosis	0.000228	0.000799	CcSEcCtD
Atomoxetine—Mental disorder—Methotrexate—multiple sclerosis	0.000228	0.000799	CcSEcCtD
Atomoxetine—Malnutrition—Methotrexate—multiple sclerosis	0.000226	0.000794	CcSEcCtD
Atomoxetine—Dyspepsia—Dexamethasone—multiple sclerosis	0.000223	0.000784	CcSEcCtD
Atomoxetine—Dyspepsia—Betamethasone—multiple sclerosis	0.000223	0.000784	CcSEcCtD
Atomoxetine—Urticaria—Triamcinolone—multiple sclerosis	0.000222	0.000779	CcSEcCtD
Atomoxetine—Urticaria—Methylprednisolone—multiple sclerosis	0.000222	0.000778	CcSEcCtD
Atomoxetine—Dysgeusia—Methotrexate—multiple sclerosis	0.000222	0.000777	CcSEcCtD
Atomoxetine—Body temperature increased—Triamcinolone—multiple sclerosis	0.000221	0.000776	CcSEcCtD
Atomoxetine—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000221	0.000774	CcSEcCtD
Atomoxetine—Decreased appetite—Betamethasone—multiple sclerosis	0.000221	0.000774	CcSEcCtD
Atomoxetine—Decreased appetite—Dexamethasone—multiple sclerosis	0.000221	0.000774	CcSEcCtD
Atomoxetine—Nausea—Mitoxantrone—multiple sclerosis	0.00022	0.000772	CcSEcCtD
Atomoxetine—Infection—Prednisone—multiple sclerosis	0.00022	0.00077	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000219	0.000769	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000219	0.000769	CcSEcCtD
Atomoxetine—Back pain—Methotrexate—multiple sclerosis	0.000219	0.000768	CcSEcCtD
Atomoxetine—Fatigue—Dexamethasone—multiple sclerosis	0.000219	0.000767	CcSEcCtD
Atomoxetine—Fatigue—Betamethasone—multiple sclerosis	0.000219	0.000767	CcSEcCtD
Atomoxetine—Shock—Prednisone—multiple sclerosis	0.000217	0.000763	CcSEcCtD
Atomoxetine—Pain—Betamethasone—multiple sclerosis	0.000217	0.000761	CcSEcCtD
Atomoxetine—Pain—Dexamethasone—multiple sclerosis	0.000217	0.000761	CcSEcCtD
Atomoxetine—Nervous system disorder—Prednisone—multiple sclerosis	0.000217	0.00076	CcSEcCtD
Atomoxetine—Tachycardia—Prednisone—multiple sclerosis	0.000216	0.000757	CcSEcCtD
Atomoxetine—Skin disorder—Prednisone—multiple sclerosis	0.000215	0.000753	CcSEcCtD
Atomoxetine—Hyperhidrosis—Prednisone—multiple sclerosis	0.000214	0.000749	CcSEcCtD
Atomoxetine—Vision blurred—Methotrexate—multiple sclerosis	0.000213	0.000748	CcSEcCtD
Atomoxetine—Ketoprofen—ALB—multiple sclerosis	0.000213	0.0431	CrCbGaD
Atomoxetine—Anorexia—Prednisone—multiple sclerosis	0.000211	0.000739	CcSEcCtD
Atomoxetine—Feeling abnormal—Dexamethasone—multiple sclerosis	0.000209	0.000734	CcSEcCtD
Atomoxetine—Feeling abnormal—Betamethasone—multiple sclerosis	0.000209	0.000734	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000207	0.000728	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000207	0.000728	CcSEcCtD
Atomoxetine—Vertigo—Methotrexate—multiple sclerosis	0.000203	0.000713	CcSEcCtD
Atomoxetine—Urticaria—Betamethasone—multiple sclerosis	0.000202	0.000707	CcSEcCtD
Atomoxetine—Urticaria—Dexamethasone—multiple sclerosis	0.000202	0.000707	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.000201	0.000706	CcSEcCtD
Atomoxetine—Dizziness—Prednisolone—multiple sclerosis	0.000201	0.000705	CcSEcCtD
Atomoxetine—Asthenia—Triamcinolone—multiple sclerosis	0.000201	0.000704	CcSEcCtD
Atomoxetine—Abdominal pain—Betamethasone—multiple sclerosis	0.000201	0.000704	CcSEcCtD
Atomoxetine—Abdominal pain—Dexamethasone—multiple sclerosis	0.000201	0.000704	CcSEcCtD
Atomoxetine—Body temperature increased—Betamethasone—multiple sclerosis	0.000201	0.000704	CcSEcCtD
Atomoxetine—Body temperature increased—Dexamethasone—multiple sclerosis	0.000201	0.000704	CcSEcCtD
Atomoxetine—Asthenia—Methylprednisolone—multiple sclerosis	0.0002	0.000702	CcSEcCtD
Atomoxetine—Insomnia—Prednisone—multiple sclerosis	0.0002	0.000701	CcSEcCtD
Atomoxetine—Paraesthesia—Prednisone—multiple sclerosis	0.000198	0.000696	CcSEcCtD
Atomoxetine—Pruritus—Triamcinolone—multiple sclerosis	0.000198	0.000694	CcSEcCtD
Atomoxetine—Cough—Methotrexate—multiple sclerosis	0.000197	0.000693	CcSEcCtD
Atomoxetine—Pruritus—Methylprednisolone—multiple sclerosis	0.000197	0.000693	CcSEcCtD
Atomoxetine—Convulsion—Methotrexate—multiple sclerosis	0.000196	0.000688	CcSEcCtD
Atomoxetine—Dyspepsia—Prednisone—multiple sclerosis	0.000194	0.000682	CcSEcCtD
Atomoxetine—Arthralgia—Methotrexate—multiple sclerosis	0.000193	0.000676	CcSEcCtD
Atomoxetine—Myalgia—Methotrexate—multiple sclerosis	0.000193	0.000676	CcSEcCtD
Atomoxetine—Chest pain—Methotrexate—multiple sclerosis	0.000193	0.000676	CcSEcCtD
Atomoxetine—Decreased appetite—Prednisone—multiple sclerosis	0.000192	0.000674	CcSEcCtD
Atomoxetine—Rash—Prednisolone—multiple sclerosis	0.000192	0.000673	CcSEcCtD
Atomoxetine—Dermatitis—Prednisolone—multiple sclerosis	0.000192	0.000672	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.000191	0.000671	CcSEcCtD
Atomoxetine—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000191	0.00067	CcSEcCtD
Atomoxetine—Fatigue—Prednisone—multiple sclerosis	0.00019	0.000668	CcSEcCtD
Atomoxetine—Headache—Prednisolone—multiple sclerosis	0.00019	0.000668	CcSEcCtD
Atomoxetine—Constipation—Prednisone—multiple sclerosis	0.000189	0.000663	CcSEcCtD
Atomoxetine—Dizziness—Triamcinolone—multiple sclerosis	0.000185	0.000649	CcSEcCtD
Atomoxetine—Dizziness—Methylprednisolone—multiple sclerosis	0.000184	0.000647	CcSEcCtD
Atomoxetine—Infection—Methotrexate—multiple sclerosis	0.000183	0.000644	CcSEcCtD
Atomoxetine—Feeling abnormal—Prednisone—multiple sclerosis	0.000182	0.000639	CcSEcCtD
Atomoxetine—Asthenia—Dexamethasone—multiple sclerosis	0.000182	0.000639	CcSEcCtD
Atomoxetine—Asthenia—Betamethasone—multiple sclerosis	0.000182	0.000639	CcSEcCtD
Atomoxetine—Nervous system disorder—Methotrexate—multiple sclerosis	0.000181	0.000635	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Prednisone—multiple sclerosis	0.000181	0.000634	CcSEcCtD
Atomoxetine—Nausea—Prednisolone—multiple sclerosis	0.000181	0.000634	CcSEcCtD
Atomoxetine—Pruritus—Dexamethasone—multiple sclerosis	0.00018	0.00063	CcSEcCtD
Atomoxetine—Pruritus—Betamethasone—multiple sclerosis	0.00018	0.00063	CcSEcCtD
Atomoxetine—Skin disorder—Methotrexate—multiple sclerosis	0.000179	0.000629	CcSEcCtD
Atomoxetine—Hyperhidrosis—Methotrexate—multiple sclerosis	0.000179	0.000626	CcSEcCtD
Atomoxetine—Vomiting—Triamcinolone—multiple sclerosis	0.000178	0.000624	CcSEcCtD
Atomoxetine—Vomiting—Methylprednisolone—multiple sclerosis	0.000177	0.000622	CcSEcCtD
Atomoxetine—Rash—Triamcinolone—multiple sclerosis	0.000176	0.000619	CcSEcCtD
Atomoxetine—Dermatitis—Triamcinolone—multiple sclerosis	0.000176	0.000618	CcSEcCtD
Atomoxetine—Anorexia—Methotrexate—multiple sclerosis	0.000176	0.000618	CcSEcCtD
Atomoxetine—Rash—Methylprednisolone—multiple sclerosis	0.000176	0.000617	CcSEcCtD
Atomoxetine—Dermatitis—Methylprednisolone—multiple sclerosis	0.000176	0.000617	CcSEcCtD
Atomoxetine—Urticaria—Prednisone—multiple sclerosis	0.000176	0.000616	CcSEcCtD
Atomoxetine—Headache—Triamcinolone—multiple sclerosis	0.000175	0.000615	CcSEcCtD
Atomoxetine—Headache—Methylprednisolone—multiple sclerosis	0.000175	0.000613	CcSEcCtD
Atomoxetine—Abdominal pain—Prednisone—multiple sclerosis	0.000175	0.000613	CcSEcCtD
Atomoxetine—Body temperature increased—Prednisone—multiple sclerosis	0.000175	0.000613	CcSEcCtD
Atomoxetine—Diarrhoea—Dexamethasone—multiple sclerosis	0.000174	0.000609	CcSEcCtD
Atomoxetine—Diarrhoea—Betamethasone—multiple sclerosis	0.000174	0.000609	CcSEcCtD
Atomoxetine—Nortriptyline—ALB—multiple sclerosis	0.00017	0.0344	CrCbGaD
Atomoxetine—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	0.000168	0.00059	CcSEcCtD
Atomoxetine—Dizziness—Dexamethasone—multiple sclerosis	0.000168	0.000589	CcSEcCtD
Atomoxetine—Dizziness—Betamethasone—multiple sclerosis	0.000168	0.000589	CcSEcCtD
Atomoxetine—Insomnia—Methotrexate—multiple sclerosis	0.000167	0.000586	CcSEcCtD
Atomoxetine—Nausea—Triamcinolone—multiple sclerosis	0.000166	0.000583	CcSEcCtD
Atomoxetine—Paraesthesia—Methotrexate—multiple sclerosis	0.000166	0.000582	CcSEcCtD
Atomoxetine—Nausea—Methylprednisolone—multiple sclerosis	0.000166	0.000581	CcSEcCtD
Atomoxetine—Somnolence—Methotrexate—multiple sclerosis	0.000164	0.000576	CcSEcCtD
Atomoxetine—Dyspepsia—Methotrexate—multiple sclerosis	0.000163	0.00057	CcSEcCtD
Atomoxetine—Vomiting—Dexamethasone—multiple sclerosis	0.000161	0.000566	CcSEcCtD
Atomoxetine—Vomiting—Betamethasone—multiple sclerosis	0.000161	0.000566	CcSEcCtD
Atomoxetine—Decreased appetite—Methotrexate—multiple sclerosis	0.000161	0.000563	CcSEcCtD
Atomoxetine—Rash—Betamethasone—multiple sclerosis	0.00016	0.000561	CcSEcCtD
Atomoxetine—Rash—Dexamethasone—multiple sclerosis	0.00016	0.000561	CcSEcCtD
Atomoxetine—Dermatitis—Dexamethasone—multiple sclerosis	0.00016	0.000561	CcSEcCtD
Atomoxetine—Dermatitis—Betamethasone—multiple sclerosis	0.00016	0.000561	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.000159	0.000559	CcSEcCtD
Atomoxetine—Fatigue—Methotrexate—multiple sclerosis	0.000159	0.000559	CcSEcCtD
Atomoxetine—Headache—Dexamethasone—multiple sclerosis	0.000159	0.000558	CcSEcCtD
Atomoxetine—Headache—Betamethasone—multiple sclerosis	0.000159	0.000558	CcSEcCtD
Atomoxetine—Asthenia—Prednisone—multiple sclerosis	0.000159	0.000556	CcSEcCtD
Atomoxetine—Pain—Methotrexate—multiple sclerosis	0.000158	0.000554	CcSEcCtD
Atomoxetine—Pruritus—Prednisone—multiple sclerosis	0.000156	0.000548	CcSEcCtD
Atomoxetine—Feeling abnormal—Methotrexate—multiple sclerosis	0.000152	0.000534	CcSEcCtD
Atomoxetine—Diarrhoea—Prednisone—multiple sclerosis	0.000151	0.00053	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.000151	0.00053	CcSEcCtD
Atomoxetine—Nausea—Betamethasone—multiple sclerosis	0.000151	0.000529	CcSEcCtD
Atomoxetine—Nausea—Dexamethasone—multiple sclerosis	0.000151	0.000529	CcSEcCtD
Atomoxetine—Urticaria—Methotrexate—multiple sclerosis	0.000147	0.000515	CcSEcCtD
Atomoxetine—Dizziness—Prednisone—multiple sclerosis	0.000146	0.000513	CcSEcCtD
Atomoxetine—Abdominal pain—Methotrexate—multiple sclerosis	0.000146	0.000512	CcSEcCtD
Atomoxetine—Body temperature increased—Methotrexate—multiple sclerosis	0.000146	0.000512	CcSEcCtD
Atomoxetine—Vomiting—Prednisone—multiple sclerosis	0.00014	0.000493	CcSEcCtD
Atomoxetine—Rash—Prednisone—multiple sclerosis	0.000139	0.000489	CcSEcCtD
Atomoxetine—Dermatitis—Prednisone—multiple sclerosis	0.000139	0.000488	CcSEcCtD
Atomoxetine—Headache—Prednisone—multiple sclerosis	0.000138	0.000486	CcSEcCtD
Atomoxetine—Asthenia—Methotrexate—multiple sclerosis	0.000132	0.000465	CcSEcCtD
Atomoxetine—Nausea—Prednisone—multiple sclerosis	0.000131	0.00046	CcSEcCtD
Atomoxetine—Pruritus—Methotrexate—multiple sclerosis	0.000131	0.000458	CcSEcCtD
Atomoxetine—Diarrhoea—Methotrexate—multiple sclerosis	0.000126	0.000443	CcSEcCtD
Atomoxetine—Dizziness—Methotrexate—multiple sclerosis	0.000122	0.000428	CcSEcCtD
Atomoxetine—Vomiting—Methotrexate—multiple sclerosis	0.000117	0.000412	CcSEcCtD
Atomoxetine—Rash—Methotrexate—multiple sclerosis	0.000116	0.000408	CcSEcCtD
Atomoxetine—Dermatitis—Methotrexate—multiple sclerosis	0.000116	0.000408	CcSEcCtD
Atomoxetine—Headache—Methotrexate—multiple sclerosis	0.000116	0.000406	CcSEcCtD
Atomoxetine—Nausea—Methotrexate—multiple sclerosis	0.00011	0.000385	CcSEcCtD
Atomoxetine—HTR1B—Signaling by GPCR—CCL5—multiple sclerosis	4.66e-05	0.000344	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—IL2RA—multiple sclerosis	4.66e-05	0.000343	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—CCR5—multiple sclerosis	4.63e-05	0.000341	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—PTGER4—multiple sclerosis	4.57e-05	0.000336	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—CNR1—multiple sclerosis	4.56e-05	0.000336	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—IL2RA—multiple sclerosis	4.56e-05	0.000336	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—RGS1—multiple sclerosis	4.54e-05	0.000334	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CXCL13—multiple sclerosis	4.53e-05	0.000334	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CCR1—multiple sclerosis	4.53e-05	0.000334	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—CXCL10—multiple sclerosis	4.52e-05	0.000333	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—CXCR3—multiple sclerosis	4.41e-05	0.000325	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CCL3—multiple sclerosis	4.38e-05	0.000323	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CYP24A1—multiple sclerosis	4.37e-05	0.000322	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CYP27B1—multiple sclerosis	4.37e-05	0.000322	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—CNR1—multiple sclerosis	4.36e-05	0.000321	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CCL3—multiple sclerosis	4.35e-05	0.00032	CbGpPWpGaD
Atomoxetine—SLC6A3—Neuronal System—MAPK1—multiple sclerosis	4.34e-05	0.00032	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—CCR5—multiple sclerosis	4.32e-05	0.000319	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—GPR65—multiple sclerosis	4.3e-05	0.000317	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—CCR2—multiple sclerosis	4.29e-05	0.000316	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—CCR5—multiple sclerosis	4.29e-05	0.000316	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	4.28e-05	0.000315	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—IL2RA—multiple sclerosis	4.26e-05	0.000314	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CCL3—multiple sclerosis	4.26e-05	0.000314	CbGpPWpGaD
Atomoxetine—SLC6A2—Transmembrane transport of small molecules—ALB—multiple sclerosis	4.25e-05	0.000313	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—IL2RA—multiple sclerosis	4.23e-05	0.000312	CbGpPWpGaD
Atomoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—multiple sclerosis	4.22e-05	0.000311	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—PTGER4—multiple sclerosis	4.22e-05	0.000311	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—POMC—multiple sclerosis	4.21e-05	0.00031	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—CCR5—multiple sclerosis	4.2e-05	0.00031	CbGpPWpGaD
Atomoxetine—HTR2A—SIDS Susceptibility Pathways—IL6—multiple sclerosis	4.19e-05	0.000309	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PTGER4—multiple sclerosis	4.19e-05	0.000308	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—PGR—multiple sclerosis	4.16e-05	0.000306	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—IL2RA—multiple sclerosis	4.14e-05	0.000305	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PGR—multiple sclerosis	4.12e-05	0.000304	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR ligand binding—CCL2—multiple sclerosis	4.12e-05	0.000304	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—CXCL10—multiple sclerosis	4.11e-05	0.000302	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PTGER4—multiple sclerosis	4.1e-05	0.000302	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CXCR3—multiple sclerosis	4.07e-05	0.0003	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CXCR3—multiple sclerosis	4.04e-05	0.000298	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PGR—multiple sclerosis	4.04e-05	0.000297	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CD28—multiple sclerosis	4.04e-05	0.000297	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CYP27B1—multiple sclerosis	4.02e-05	0.000296	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CYP24A1—multiple sclerosis	4.02e-05	0.000296	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CD28—multiple sclerosis	4.01e-05	0.000295	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GPC5—multiple sclerosis	4e-05	0.000295	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—IL2—multiple sclerosis	4e-05	0.000295	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—IL6—multiple sclerosis	3.98e-05	0.000293	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CCR2—multiple sclerosis	3.96e-05	0.000292	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—CNR1—multiple sclerosis	3.96e-05	0.000292	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CXCR3—multiple sclerosis	3.96e-05	0.000292	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CXCL13—multiple sclerosis	3.93e-05	0.00029	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CCR1—multiple sclerosis	3.93e-05	0.00029	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CCR2—multiple sclerosis	3.93e-05	0.00029	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—CXCL10—multiple sclerosis	3.93e-05	0.000289	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CD28—multiple sclerosis	3.92e-05	0.000289	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—CCL5—multiple sclerosis	3.89e-05	0.000287	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CCR2—multiple sclerosis	3.85e-05	0.000284	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—MMP9—multiple sclerosis	3.79e-05	0.000279	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmembrane transport of small molecules—ALB—multiple sclerosis	3.76e-05	0.000277	CbGpPWpGaD
Atomoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—multiple sclerosis	3.74e-05	0.000275	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—SRM—multiple sclerosis	3.73e-05	0.000275	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—POMC—multiple sclerosis	3.72e-05	0.000274	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—POMC—multiple sclerosis	3.69e-05	0.000272	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GPC5—multiple sclerosis	3.68e-05	0.000271	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CNR1—multiple sclerosis	3.66e-05	0.000269	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CNR1—multiple sclerosis	3.63e-05	0.000267	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—POMC—multiple sclerosis	3.62e-05	0.000266	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—CXCL10—multiple sclerosis	3.57e-05	0.000263	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CNR1—multiple sclerosis	3.55e-05	0.000262	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—CCL5—multiple sclerosis	3.53e-05	0.00026	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—CCR5—multiple sclerosis	3.51e-05	0.000258	CbGpPWpGaD
Atomoxetine—CYP3A4—Biological oxidations—POMC—multiple sclerosis	3.46e-05	0.000255	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—IL2RA—multiple sclerosis	3.46e-05	0.000255	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—CCL5—multiple sclerosis	3.38e-05	0.000249	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—POMC—multiple sclerosis	3.38e-05	0.000249	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—STAT3—multiple sclerosis	3.37e-05	0.000248	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—POMC—multiple sclerosis	3.35e-05	0.000247	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—RRM1—multiple sclerosis	3.32e-05	0.000244	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—CCL2—multiple sclerosis	3.31e-05	0.000244	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CXCL10—multiple sclerosis	3.29e-05	0.000243	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—POMC—multiple sclerosis	3.28e-05	0.000242	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—CCL2—multiple sclerosis	3.28e-05	0.000242	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CXCL10—multiple sclerosis	3.27e-05	0.000241	CbGpPWpGaD
Atomoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—multiple sclerosis	3.25e-05	0.000239	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CCL3—multiple sclerosis	3.23e-05	0.000238	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—CCL2—multiple sclerosis	3.21e-05	0.000237	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CXCL10—multiple sclerosis	3.2e-05	0.000236	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—CCR5—multiple sclerosis	3.18e-05	0.000235	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—IL2RA—multiple sclerosis	3.14e-05	0.000231	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—MYC—multiple sclerosis	3.13e-05	0.00023	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—TGFB1—multiple sclerosis	3.12e-05	0.00023	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PTGER4—multiple sclerosis	3.11e-05	0.000229	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—CCL5—multiple sclerosis	3.07e-05	0.000226	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—MAPK1—multiple sclerosis	3.06e-05	0.000225	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PGR—multiple sclerosis	3.06e-05	0.000225	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—RRM1—multiple sclerosis	3.05e-05	0.000225	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—CCR5—multiple sclerosis	3.05e-05	0.000224	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—TYK2—multiple sclerosis	3e-05	0.000221	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—IL2RA—multiple sclerosis	3e-05	0.000221	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CXCR3—multiple sclerosis	3e-05	0.000221	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—TYK2—multiple sclerosis	2.98e-05	0.00022	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CD28—multiple sclerosis	2.97e-05	0.000219	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CCR2—multiple sclerosis	2.92e-05	0.000215	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—TYK2—multiple sclerosis	2.92e-05	0.000215	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CD86—multiple sclerosis	2.88e-05	0.000212	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CD86—multiple sclerosis	2.86e-05	0.000211	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CCL5—multiple sclerosis	2.84e-05	0.000209	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CCL5—multiple sclerosis	2.81e-05	0.000207	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CCL3—multiple sclerosis	2.8e-05	0.000206	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CD86—multiple sclerosis	2.8e-05	0.000206	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—CCR5—multiple sclerosis	2.77e-05	0.000204	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CCL5—multiple sclerosis	2.76e-05	0.000203	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—IL2—multiple sclerosis	2.75e-05	0.000203	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—POMC—multiple sclerosis	2.74e-05	0.000202	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—IL2—multiple sclerosis	2.73e-05	0.000201	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—IL2RA—multiple sclerosis	2.73e-05	0.000201	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PTGER4—multiple sclerosis	2.7e-05	0.000199	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CNR1—multiple sclerosis	2.69e-05	0.000198	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—IL2—multiple sclerosis	2.67e-05	0.000197	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PGR—multiple sclerosis	2.66e-05	0.000196	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	2.63e-05	0.000194	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	2.63e-05	0.000194	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—SPP1—multiple sclerosis	2.63e-05	0.000193	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CXCR3—multiple sclerosis	2.61e-05	0.000192	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—SPP1—multiple sclerosis	2.61e-05	0.000192	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CD28—multiple sclerosis	2.58e-05	0.00019	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	2.57e-05	0.000189	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CCR5—multiple sclerosis	2.55e-05	0.000188	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—SPP1—multiple sclerosis	2.55e-05	0.000188	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CCR2—multiple sclerosis	2.53e-05	0.000187	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CCR5—multiple sclerosis	2.53e-05	0.000187	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—IL2RA—multiple sclerosis	2.52e-05	0.000185	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—IL2—multiple sclerosis	2.5e-05	0.000184	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—IL2RA—multiple sclerosis	2.5e-05	0.000184	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—POMC—multiple sclerosis	2.49e-05	0.000183	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CCR5—multiple sclerosis	2.48e-05	0.000183	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—IL2—multiple sclerosis	2.48e-05	0.000183	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—IL2RA—multiple sclerosis	2.45e-05	0.00018	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—CCL2—multiple sclerosis	2.44e-05	0.000179	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—IL2—multiple sclerosis	2.43e-05	0.000179	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CXCL10—multiple sclerosis	2.43e-05	0.000179	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GPC5—multiple sclerosis	2.41e-05	0.000177	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—POMC—multiple sclerosis	2.38e-05	0.000175	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—IL6—multiple sclerosis	2.35e-05	0.000173	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CNR1—multiple sclerosis	2.34e-05	0.000172	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—APOE—multiple sclerosis	2.32e-05	0.000171	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—APOE—multiple sclerosis	2.31e-05	0.00017	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—APOE—multiple sclerosis	2.26e-05	0.000166	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—TYK2—multiple sclerosis	2.21e-05	0.000163	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	2.21e-05	0.000163	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—POMC—multiple sclerosis	2.16e-05	0.000159	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CD86—multiple sclerosis	2.12e-05	0.000156	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—CCL2—multiple sclerosis	2.11e-05	0.000156	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CXCL10—multiple sclerosis	2.11e-05	0.000155	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CD80—multiple sclerosis	2.1e-05	0.000155	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CCL5—multiple sclerosis	2.09e-05	0.000154	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CD80—multiple sclerosis	2.09e-05	0.000154	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CD80—multiple sclerosis	2.04e-05	0.00015	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—IL2—multiple sclerosis	2.03e-05	0.000149	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	2.01e-05	0.000148	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—POMC—multiple sclerosis	2e-05	0.000147	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—RRM1—multiple sclerosis	1.99e-05	0.000147	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—POMC—multiple sclerosis	1.98e-05	0.000146	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CCL2—multiple sclerosis	1.95e-05	0.000144	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—POMC—multiple sclerosis	1.94e-05	0.000143	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CCL2—multiple sclerosis	1.94e-05	0.000143	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—SPP1—multiple sclerosis	1.93e-05	0.000142	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—TYK2—multiple sclerosis	1.92e-05	0.000141	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—MAPK1—multiple sclerosis	1.91e-05	0.000141	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—BCHE—multiple sclerosis	1.9e-05	0.00014	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CCL2—multiple sclerosis	1.9e-05	0.00014	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—MAPK1—multiple sclerosis	1.9e-05	0.00014	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CCR5—multiple sclerosis	1.88e-05	0.000139	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—MAPK1—multiple sclerosis	1.86e-05	0.000137	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IL2RA—multiple sclerosis	1.85e-05	0.000137	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CD86—multiple sclerosis	1.84e-05	0.000136	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—IL2—multiple sclerosis	1.84e-05	0.000136	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CCL5—multiple sclerosis	1.81e-05	0.000134	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TYK2—multiple sclerosis	1.77e-05	0.000131	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TYK2—multiple sclerosis	1.76e-05	0.00013	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—IL2—multiple sclerosis	1.76e-05	0.00013	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—BCHE—multiple sclerosis	1.75e-05	0.000129	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TYK2—multiple sclerosis	1.72e-05	0.000127	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—APOE—multiple sclerosis	1.71e-05	0.000126	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—SPP1—multiple sclerosis	1.68e-05	0.000124	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CCR5—multiple sclerosis	1.63e-05	0.00012	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IL2RA—multiple sclerosis	1.61e-05	0.000119	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—IL2—multiple sclerosis	1.6e-05	0.000118	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CD80—multiple sclerosis	1.55e-05	0.000114	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—APOE—multiple sclerosis	1.49e-05	0.000109	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—IL2—multiple sclerosis	1.48e-05	0.000109	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—POMC—multiple sclerosis	1.47e-05	0.000108	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—IL6—multiple sclerosis	1.47e-05	0.000108	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—IL2—multiple sclerosis	1.46e-05	0.000108	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—IL6—multiple sclerosis	1.46e-05	0.000107	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CCL2—multiple sclerosis	1.44e-05	0.000106	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—IL2—multiple sclerosis	1.43e-05	0.000106	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—IL6—multiple sclerosis	1.43e-05	0.000105	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—MAPK1—multiple sclerosis	1.41e-05	0.000104	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—MMP9—multiple sclerosis	1.4e-05	0.000103	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—MMP9—multiple sclerosis	1.39e-05	0.000102	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—MMP9—multiple sclerosis	1.36e-05	0.0001	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CD80—multiple sclerosis	1.34e-05	9.9e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TYK2—multiple sclerosis	1.31e-05	9.62e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—POMC—multiple sclerosis	1.28e-05	9.4e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CCL2—multiple sclerosis	1.25e-05	9.2e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—STAT3—multiple sclerosis	1.24e-05	9.15e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—STAT3—multiple sclerosis	1.23e-05	9.08e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—MAPK1—multiple sclerosis	1.22e-05	9e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—STAT3—multiple sclerosis	1.21e-05	8.89e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—MYC—multiple sclerosis	1.15e-05	8.5e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TGFB1—multiple sclerosis	1.15e-05	8.48e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—APOE—multiple sclerosis	1.15e-05	8.44e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—MYC—multiple sclerosis	1.15e-05	8.44e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—BCHE—multiple sclerosis	1.15e-05	8.44e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TGFB1—multiple sclerosis	1.14e-05	8.42e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TYK2—multiple sclerosis	1.13e-05	8.36e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—MAPK1—multiple sclerosis	1.13e-05	8.32e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—MYC—multiple sclerosis	1.12e-05	8.26e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—MAPK1—multiple sclerosis	1.12e-05	8.25e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TGFB1—multiple sclerosis	1.12e-05	8.24e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—MAPK1—multiple sclerosis	1.1e-05	8.08e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IL2—multiple sclerosis	1.09e-05	8.01e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—IL6—multiple sclerosis	1.08e-05	7.97e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—APOE—multiple sclerosis	1.05e-05	7.76e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MMP9—multiple sclerosis	1.03e-05	7.58e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—POMC—multiple sclerosis	9.84e-06	7.25e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IL2—multiple sclerosis	9.44e-06	6.95e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—IL6—multiple sclerosis	9.39e-06	6.92e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—STAT3—multiple sclerosis	9.15e-06	6.74e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—POMC—multiple sclerosis	9.05e-06	6.67e-05	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—ALB—multiple sclerosis	8.97e-06	6.61e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MMP9—multiple sclerosis	8.93e-06	6.58e-05	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—IL6—multiple sclerosis	8.67e-06	6.39e-05	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—IL6—multiple sclerosis	8.61e-06	6.34e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MYC—multiple sclerosis	8.5e-06	6.26e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TGFB1—multiple sclerosis	8.48e-06	6.25e-05	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—IL6—multiple sclerosis	8.43e-06	6.21e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MAPK1—multiple sclerosis	8.31e-06	6.12e-05	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—ALB—multiple sclerosis	8.25e-06	6.08e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—STAT3—multiple sclerosis	7.94e-06	5.85e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MYC—multiple sclerosis	7.38e-06	5.44e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TGFB1—multiple sclerosis	7.36e-06	5.42e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MAPK1—multiple sclerosis	7.22e-06	5.32e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—APOE—multiple sclerosis	6.89e-06	5.07e-05	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IL6—multiple sclerosis	6.39e-06	4.71e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—POMC—multiple sclerosis	5.92e-06	4.36e-05	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IL6—multiple sclerosis	5.55e-06	4.09e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—ALB—multiple sclerosis	5.4e-06	3.97e-05	CbGpPWpGaD
